Arylated Camphene Compounds Selective CB2 Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for neurological and neurodegenerative diseases often rely on CB1 receptor agonists, which can cause undesirable psychoactive effects, limiting their therapeutic value, while CB2 receptor stimulants with selective action are needed to treat conditions like cerebral hypoxia-ischemia, Alzheimer's, and Huntington's disease without central nervous system side effects.
Innovation Solution
Development of arylated camphene compounds that selectively stimulate CB2 receptors, formulated into pharmaceutical compositions for treating diseases and disorders associated with CB2 receptor stimulation, including neurological and neurodegenerative conditions, without the psychoactive effects of CB1 agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB1 receptor agonists are used to treat neurological and neurodegenerative diseases, then therapeutic effects are achieved, but psychoactive side effects occur
Solution Approach 1:
The invention segments the cannabinoid receptor system by developing compounds that selectively target only CB2 receptors, separating the therapeutic effects from the psychoactive side effects associated with CB1 receptor activation. This selectivity allows treatment of neurological conditions without central nervous system psychoactive effects.
Solution Approach 2:
The arylated camphene compounds exhibit local quality by demonstrating selective affinity for CB2 receptors over CB1 receptors. This selective binding property enables the compounds to produce therapeutic effects in peripheral and neurological tissues while avoiding the psychoactive effects mediated by central CB1 receptors.
2Object-affected harmful factors
If selective CB2 receptor stimulants are developed, then psychoactive side effects are avoided, but therapeutic efficacy for neurological conditions must be maintained
Solution Approach 1:
The invention modifies the chemical structure of camphene by introducing aryl groups at specific positions (C-2, C-3, or C-4) to optimize the compounds' affinity for CB2 receptors. These structural parameter changes enhance selective CB2 stimulation while maintaining or improving therapeutic efficacy for neurological and neurodegenerative conditions.
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 1G
AI summary
The present invention relates to arylated camphenes, processes for their preparation and uses thereof for the manufacture of medicaments for the treatment of diseases, disorders or conditions associated with, or benefiting from stimulation of CB2 receptors.